Trailblazing a New Frontier in ALS Treatment: Dr. Claire Clelland’s Bold CRISPR Strategy to Rewrite the Future

Honoring Lou Gehrig | Lou Gehrig’s Day 2025

From One Family to a Movement: ALS Care and Support Foundation, India

Unlocking ALS Risk in South Asian Populations: Inside a Groundbreaking Genetic Study Led by India and the UK

“Collective action”: Why Healthy Controls Are Critical in ALS Research

Turning Sight into Insight: How Amydis Is Using the Retina to Rethink ALS Screening and Diagnostics 

“Still Showing Up”: Siddu Tummala on Life, ALS, and the Burden of Hope

Expanding the Frontiers of ALS Research: South Korea Joins the Target ALS Global Study

Paying It Forward: The Power of Using Our Voice for Impact

Advancing ALS Research in India Through Global Collaboration

Target ALS Launches “Behind Every Breakthrough” Campaign for ALS Awareness Month to Spotlight Progress and People Driving ALS Research Forward

Pioneering the Next Generation of ALS Therapeutics: Announcing the 2025 Novel Modalities Consortia Grantees

March 2025 Newsletter

Bridging Worlds: Volkan Granit and the Unique Collaborative Spirit of Target ALS

Target ALS Highlighted in New Case Study Released by Harvard Kennedy School Focused on Innovative Model for Collaborative Medical Research

A Trailblazer in Neuroscience and Biotech Leadership

Unveiling the Power of Diversity: The Impact of Research in Colombia

Women in Science at Target ALS: Breaking Barriers, Driving Discovery

Research, Resilience, and Representation: Dr. Leeanne McGurk Weighs In

Science on Target March 2025 Newsletter

Perseverance and Prevailing: A Seven-Year Journey in Neuroscientific Innovation

From Paris, With Love for Science: Dr. Latouche’s Groundbreaking ALS Research

Transforming the Future of ALS Research: Reflections from Our Community Outreach Event in Arizona

Unveiling the Power of Diversity: The Impact of Research in Colombia

CRISPR: A Powerful Tool Used to Advance ALS Research

Empowering Puerto Rico’s ALS Community: The Impact of Research

2024 Year In Review

ALS Arizona: Empowering Lives, Strengthening Community, and Advancing Progress

Mind the Gap: Sabine Liebscher is Connecting the Dots of ALS

Progress and Impact: 2022 Basic Biology Grants

Tofersen Shows Promising Results in SOD1 ALS Treatment—A New Hope for Genetic Therapies

Unveiling the Path to ALS Therapies: A Journey from Flies to Humans

Accelerating ALS Research: A Scientist’s Experience with the Target ALS Data Engine

Digital Biomarkers – An Opportunity to Overcome the Limits of Traditional Rating Scales?

Researchers Report on the Opposing Roles of p38α Phosphorylation and Protein Arginine Methyltransferase 1 (PRMT1) Methylation in TDP-43 Proteinopathy

Together For Rare: Judith Chavira on Diversity in ALS Research

Diane Pascot: A Journey of Hope and Courage

January 2025 Newsletter

ALS Disease Statistics: Insights from Latest Research

Advancing ALS Research: Key Insights and Breakthroughs from the 2024 International Symposium on ALS/MND

Advancing ALS Research with Stem Cell Resources and Targeted Reagents: The Role of Target ALS in the Quest for Effective Treatments

December 2024 Newsletter

Collaborating for Progress: ALS United Greater New York and Target ALS

Dan Doctoroff: From Transforming New York City to Building a World Where Everyone with ALS Lives 

Navigating Life After an ALS Diagnosis: Understanding Progression, Stages, and What to Expect

November 2024 Newsletter

Target ALS Attends NEALS Conference: Insights into Groundbreaking Research

Science on Target November 2024 Newsletter

A Labor of Love: Theresa Whitlock-Wild’s Unwavering Commitment to Families Affected by ALS

A Father’s Fight, A Daughter’s Strength: Navigating Life with ALS

Addressing Inequities in ALS Healthcare: The Critical Need for Diversity in Research

Veterans and ALS: A Critical Population for Advancing Research

A Race Against Time: A Story of ALS and Caregiving

Breaking Down Barriers in ALS Research: New Validated pTDP-43 Antibody Now Available Globally

Five Innovative Collaborative Projects Awarded Biomarker Consortia Grant Funding

Dan Doctoroff discusses future of New York, pushes for ALS funding on Spectrum News

Target ALS featured in ALS News Today: ALS respiratory data now available to researchers worldwide

Target ALS October 2024 Newsletter

Two Studies Awarded Funding to Accelerate Novel ALS Therapies Through In-Vivo Proof-of-Concept

Target ALS Partners with ZEPHYRx to Enhance Global ALS Research Through Data Integration

Updates from our Research Cores: Expanding our Cellular Model Toolkit

Target ALS September 2024 Newsletter

Science on Target: Target ALS Postmortem Tissue Core Facilitates Groundbreaking Research on SOD1 Protein Aggregation

Target ALS and Modality.AI Collaborate in Multimodal Study of ALS

The Target ALS Data Engine Just Got Bigger: New Data Available for Mining

Biomarker Milestone Achieved: Target Identification

Announcing the Recipients of the 2024 In Vivo Target Validation Grants in Collaboration with Biospective

Announcing the Recipients of the Basic Biology Consortia Grant

A PATH TO A WORLD WHERE EVERYONE LIVES – Highlights from the 2024 ALS Annual Meeting

Letter From Our Founder: Reflecting on 2024 Target ALS Annual Meeting

Letter From Our CEO: 2024 Target ALS Annual Meeting Remarks

Breakthroughs in Biomarker Research: Insights From Our 2024 Annual Meeting

Identifying Novel Drug Targets: Expanding the Horizons of ALS Treatment

2024 Neurology Resident Grants Recipients Announced

Drug Discovery and Development: A Glimpse into the Future of ALS Treatment

Dan Doctoroff Against ALS – Time Magazine

New Natural History Study Collection Added to Target ALS Data Portal

Target ALS raises $250 million to accelerate ALS research – ALS News Today

Target ALS Achieves Extraordinary $250 Million Capital Campaign Goal to Accelerate ALS Research

Target ALS Launches Groundbreaking Data Portal with DNAstack and Verily to Fuel Breakthroughs in ALS Research 

Target ALS Has Been Named an Official Charity Partner for the 2024 TCS New York City Marathon

Biofluid Samples from Target ALS Natural History Study Available for Global Distribution to Advance ALS Research

Target ALS 2023 Annual Report

Everyone Lives: Target ALS Newsletter Winter 2023/2024

Target ALS Celebrates 10 Years: A Decade in Review

“His Mind Helped Rebuild New York. His Body is Failing Him.” – Dan Doctoroff featured in the New York Times

Former NYC deputy mayor raises millions for ALS research while facing his own mortality – PBS News

Everyone Lives: Target ALS Newsletter Fall 2023

Why Michael Bloomberg’s Former Deputy Mayor is Raising $250 Million for ALS Research – People

Target ALS Has Been Named an Official Charity Partner for the 2023 TCS New York City Marathon

“What the Builder Built”- Dan Doctoroff featured in Curbed

The Ultimate Guide to Cognitive Impairment, Dementia, and ALS

Therapeutic Target HDAC6 and ALS

How FUS Fits into the Bigger RNA Protein Picture

RNA Therapy for ALS: A Promising Treatment

Epidemiology of ALS: Incidence, Prevalence, and Suspected Clusters

What is AAV for Gene Therapy?

Juvenile ALS: How Common is ALS in Your 20s?

The Missing Piece of ALS Research: Biomarkers

How Does an ALS Muscle Biopsy Help Researchers?

Target ALS 2021 Annual Report

How ASO Research May Help Nano-Rare ALS Patients

How Dan Doctoroff Lives With a Terminal Diagnosis – Bloomberg

The C9orf72 ALS Connection

The Role of Stress Granules in ALS

Benefits of Using Cerebrospinal Fluid Samples in Medical Research

Target ALS and Alzheimer’s Drug Discovery Foundation Announce Award Recipients for Biomarker Research

The Effects of ALS on the Digestive System

How Upper and Lower Motor Neurons Relate to ALS

Understanding the Science with Dan Elbaum, Ph.D.

Understanding the Science with Merit Cudkowicz, Ph.D.

Understanding the Science with Sarah Glass, Ph.D.

Understanding the Science with Penny Dacks

Understanding the Science with Leonard Petrucelli

Understanding the Science with Aarti Sharma

Fireside Chat with Founder, Dan Doctoroff

Understanding the Science with Robert Bowser, Ph.D.

Understanding the Science with Stanley Crooke

Understanding the Science with Susan Dickinson of AFTD

Target ALS Annual Meeting 2022 | Dan Doctoroff

Understanding the Science – Spotlight on Biomarkers

Interview with Emanuele Buratti, Ph.D. | 2023 Target ALS Annual Meeting

Interview with Jenna Gregory, Ph.D. | 2023 Target ALS Annual Meeting

Interview with Alexander McCampbell, Ph.D.| 2023 Target ALS Annual Meeting

Interview with Fanny Elahi, M.D., Ph.D | 2023 Target ALS Annual Meeting

Interview with Elizabeth Buttermore, Ph.D. | 2023 Target ALS Annual Meeting

Interview with Dr. Stefan McDonough | 2023 Target ALS Annual Meeting

Interview with Sarah Glass, Ph.D. | 2023 Target ALS Annual Meeting

The Postmortem Tissue Core Team Shares Why They Do What They Do

Interview with Matt Disney, Ph.D. | 2023 Target ALS Annual Meeting

Interview with Johannes Troger, D.SC. | 2023 Target ALS Annual Meeting

Interview with Dr. Dorothy Schafer | 2023 Target ALS Annual Meeting

Interview with Dr. Jonathan Cooper Knock | 2023 Target ALS Annual Meeting

Interview with Hemali Phatnani, Ph.D. | 2023 Target ALS Annual Meeting

A Family’s Battle with ALS: Story of Hope and Determination

ALS Symptoms: What are the Most Common Symptoms and Diagnosis

ALS Genetic Mutations Explained

The Connection Between Dysphagia and ALS

Under the Microscope: Dr. Emanuele Buratti on the Role of TDP-43 in ALS Pathology

Target ALS Announces New Corporate Council Partnership Opportunity

ALS Muscle Twitching vs BFS Muscle Twitching: Knowing the Differences

Target ALS Issues Call For Proposals for ALS Biology-Focused Collaborative Projects

Leonard Florence Center for Living Offers Independence and Support for Individuals Living with ALS

Inaugural Rebecca Luker Courage Award of Recognition: Mark Calmes

Making Accessibility Accessible: John-boy’s Place and Windchime Wishes

Inaugural Rebecca Luker Courage Award of Recognition: Sandy Morris

Inaugural Rebecca Luker Courage Award of Recognition: Timothy Miller, MD/PhD

What is Bulbar-Onset ALS? Six Things to Know.

Inaugural Rebecca Luker Courage Award Unsung Hero Winner: Joumana Baroody

Winner of the Inaugural Rebecca Luker Courage Award: Merit E. Cudkowicz

n-Lorem Foundation and Columbia University Establish Silence ALS Initiative

Target ALS and Mitsubishi Tanabe Pharma America Announce Winner of the First Annual Rebecca Luker Courage Award

ALS in the Elderly: Recognizing ALS in Seniors

Interview with Dr. Joseph Lewcock | 2023 Target ALS Annual Meeting

ALS and Nutrition: How Diet Impacts ALS Patients

Sporadic ALS: Understanding Why ALS Occurs with no Family History

How ALS Affects Speech

Saying Goodbye to a Friend Who Battled ALS: Julie Giacobassi

What Do We Talk About When We Talk About Genetics?

It’s Not Just Physical: ALS, Dementia, Cognitive Impairment and Memory Loss

Diagnosing ALS: It’s Often a Year-Long Journey

False Positives and False Negatives: How ALS Can be Misdiagnosed

How to Help Someone with ALS: Tips for Friends, Family members and Caregivers

How ALS Research Studies Work

ALS and Other Motor Neuron Diseases: What’s the Difference?

The Stages of ALS: Framing the Progression of a Nonlinear Disease

Alzheimer’s Drug Discovery Foundation (ADDF) and Target ALS Announce Partnership to Accelerate Biomarker Discovery and Development

Thinking About Participating in a Clinical Trial? Here’s What You Need to Know

Giving Back Hope: Creating Resources for Children Affected by ALS

Under the Microscope: Dr. Dan Elbaum on the Role of STATHMIN-2

Reversing ALS? It’s Still Early, but ASO Therapeutics Are Generating Optimism

Baseball, the Father of Neurology and Epidemiology: Connecting the ALS Dots

Under the Microscope: Gene Yeo on RNA-Directed Therapy for ALS Caused by a C9ORF72 Mutation

Understanding ALS-Related Genes Leads to New ALS Therapeutic Insights

Complex Decisions: Predictive Genetic Testing for Family Members

Under the Microscope: Dr. Philip Wong on Searching for TDP-43 Biomarkers

Giving in the Face of ALS: A Fight to Help the ALS Community Keep Living After Diagnosis

Top 4 Things You Need to Know About ALS

How a Research Idea Transforms Into a Clinical Trial

Similarities in Neurodegenerative Disorders May Lead to New, Common Therapies

Tiny Protein, Enormous Potential: Why TDP-43 Matters

Target ALS and Mitsubishi Tanabe Pharma America Announce Rebecca Luker Courage Award Series and Call for Nominations

Target ALS 2020 Annual Report

Under the Microscope: Christine Vande Velde on Seeking Solutions for Cellular Self Defense

Under the Microscope: Sami Barmada, M.D., Ph.D. on Biomarkers and Therapeutic Targets for ALS and FTD

Finding The Light Amidst ALS: Sunny Brous’ Story

The Power of Community + ALS: Bryan Rosica’s Story

To Dad, With Love: One Daughter’s Story of a Father’s ALS Journey

From an Arm Twitch To ALS Advocacy

Target ALS Announces “Becca,” a One-Night Only Streaming Concert Fundraiser Featuring Broadway’s Best-Known Stars, in Memory of Rebecca Luker

Target ALS Announces Second Round of 2020 Grant Recipients Focused on Discovering and Developing ALS Biomarkers

Target ALS Launches The First-Ever Comprehensive Research Initiative to Discover Urgently Needed ALS Biomarkers

Research Funding Decisions Made Fair; Independent Review is Key

We Salute You: Tom’s Life Was Defined By Much, But Not By ALS

Living Life to the Fullest: Eric’s Story of Giving ALS a Run for Its Money

Tripper’s Five Tips to Take on “The Toughest Challenge” in Support of ALS Research

ALS Charity Gets Creative During COVID-19 By Taking On ‘The Toughest Challenge’

Under The Microscope: The Role of Genomics in ALS Research

Meet The Toughest Challenge For The Hardest Fight / Join Us to Make a Difference

5 Answers About ALS From Our CEO

Our ROI: Impact to Date of the Target ALS Innovation Ecosystem

‘The Unexpected Artist’: Guest Post by Ron Hoffman, Compassionate Care ALS Founder

‘Never Say Invisible’: One Family’s Perspective on Living with ALS

UNDER THE MICROSCOPE: Why TDP-43 Matters So Much in ALS Research

Under the Microscope: Sophie Parmentier-Batteur on Interrogating a Protein Compound for Possible Therapeutic Approaches to ALS and FTD

UNDER THE MICROSCOPE: Ludo Van Den Bosch on Returning to Work, Exploring Therapeutic Strategies to Battle ALS & FTD

Searching for Information, a Media Resource Offers Credible, Compassionate News and Relatable Stories to the ALS Community

Under the Microscope: Fen-Biao Gao ofUMass Medical School Explains His Now-Funded Project Targeting Biomarkers and Disease Modifiers for ALS and FTD

Building a Safer Future: How Matt’s Place Foundation is Helping ALS Patients With Home Accessibility

Target ALS and AFTD Announce $5MM in Grants for Research Targeting Treatments and Biomarkers

Target ALS and The ALS Association Announce New TDP-43-Focused Biomarker Initiative

Target ALS Annual Meeting Canceled Due to the Spread of COVID-19

Target ALS Expands Stem Cell Core to Include Innovative New Reporter Lines

What’s Next for Target ALS? A Preview of Our Work in 2020

Thanks to Your Support: $35 Million Raised in 2019

Target ALS Innovation Ecosystem Impact & Upcoming Initiatives

ALS/FTD Response Signals Resounding Desire for Collaboration

A Cancer Drug for ALS? Organization Forges Promising ALS Treatment, an Innovative Approach to Incubate Novel Therapeutics

NEWS: Target ALS-Funded Research Shows Promise in Slowing ALS Disease Progression Scientists Discover Method to Decrease Neuroinflammation and Extend Life Expectancy

150 Years Later, Still No Effective Treatment for ALS. New Research Model Offers Hope

NEWS: Target ALS Biosample Recipients Identify Three Distinct Subtypes of ALS

Target ALS & AFTD Announce Groundbreaking Partnership to Spur Drug and Biomarker Development for ALS and FTD

The Boston Globe Features Target ALS Founder, Dan Doctoroff

Target ALS Awards Six Innovative Research Teams with Additional Target Discovery Funds

American Academy of Neurology and Target ALS Partner to Accelerate ALS Research

Case Study: Collaboration Accelerates Potential ALS Treatment

Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS

Target ALS Foundation Makes Human Stem Cell Lines Accessible to Researchers

Target ALS Providing Critical Tool to Study C9ORF72 Biology

Case Study: Biomarkers Offer Optimism for People with ALS

New Biomarker Study with Academic, Industry and Philanthropic Partners

Target ALS expands core facilities access to MDA development grant awardees

Target ALS Foundation Selects RUCDR Infinite Biologics

Partnership to Uncover Connection Between Ancient Retroviruses and ALS

Biogen and Target ALS Foundation Announce $20 Million Funding Challenge

The New York Times Features Daniel L. Doctoroff, Target ALS Founder